MEDICAL BOARD STAFF REPORT

DATE REPORT ISSUED: April 26, 2013
ATTENTION: Medical Board of California
SUBJECT: Special Faculty Permit Review Committee Recommendation
STAFF CONTACT: Curtis J. Worden, Chief of Licensing

RECOMMENDED ACTION:

Board approves the recommendations of the Special Faculty Permit Review Committee (SFPRC) for appointments pursuant to Section 2168.1 of the California Business and Professions Code.

BACKGROUND AND ANALYSIS:

The Medical Board of California is authorized to issue a Special Faculty Permit (SFP) to a person who is academically eminent and meets all of the other requirements pursuant to Section 2168.1 of the California Business and Professions Code (B&P).

An individual who holds a valid SFP is authorized to practice medicine only within the medical school itself and any affiliated institutions in which the SFP holder is providing instruction as part of the medical school's educational program and for which the medical school has assumed direct responsibility.

The SFPRC is comprised of two Board members, one who is a physician and surgeon and one who is a public member, and of one representative from each of the medical schools in California. The SFPRC reviews and makes recommendations to the Board regarding the applicants applying pursuant to Section 2161.1 of the B&P.

At its March 14, 2013 meeting, the SFPRC reviewed the qualifications of one applicant from the University of California San Francisco, School of Medicine (UCSF-SOM,).

Bertil Eric Damato, M.D., Ph.D., UCSF-SOM - SFP APPLICANT:

Neal Cohen, M.D., M.P.H., M.S., UCSF, Vice Dean Academic Affairs, presented UCSF-SOM's request for Bertil Eric Damato, M.D., Ph.D., to receive a special faculty permit and the qualifications of Dr. Damato. Dr. Cohen indicated that Dr. Damato is an internationally recognized expert in the field of Ocular Oncology and is currently the President of the International Society of Ocular Oncology. He is also the Director and Clinical Lead of Liverpool Ocular Oncology Centre, which he established at the Royal Liverpool University Hospital in 1993. Dr. Damato is a highly sought after presenter at international scientific conferences and meetings. In addition, Dr. Damato has attracted trainees form around the world, who have gone back to leadership positions in their own right in their respective countries. Dr. Damato is an innovator in the field of Ocular Oncology, and his expertise in

proton beam therapy and the management of adult intraocular tumors, will provide a new level of patient care at UCSF.

Dr. Damato was the first to employ direct proton beam treatment of iris melanomas, which is an excellent approach to treating disseminated tumor in the anterior chamber angle, while preserving the eye. This innovation necessitated abandoning prevailing concepts of the time which held that proton beam was damaging to the anterior segment of the eye. The work done by Dr. Damato found that this damage did not occur when the treated volume was limited to the iris plane. His expertise in proton beam therapy will provide a new level of care to patients with intraocular tumors. In addition to proton therapy, Dr. Damato offers an exceptionally wide range of eye-conserving therapies, which include transpupillary thermotherapy, photodynamic therapy and endo- and exo-resection. As such, Dr Damato receives patients from over 32 countries and receives 700 cases per year.

Dr. Damato is the primary adult ocular oncology specialist for the entire British National Health Service and currently practices in the UK.

Dr. Damato will hold a full time faculty appointment as a Professor of Clinical Ophthalmology. Dr. Damato will be teaching medical students, residents, and fellows in the field of Ocular Oncology, along with performing surgeries at UCSF Parnassus Campus, Moffitt-Long Hospitals, and Mt. Zion Campus.

SPECIAL FACULTY PERMIT REVIEW COMMITTEE FINDINGS:

The SFPRC recommended approval of Dr. Damato for a SFP at UCSF pursuant to Business and Professions Code Section 2168 (a)(1)(A).

FISCAL CONSIDERATIONS:

None